Emerging Therapy Solutions Announces National Contract with Hemophilia Alliance Network Services for Negotiated Gene Therapy Rates
Through this contract and relationship, ETS offers its Payer, Employer and Health Plan clients a streamlined way to serve their members while providing access to care and transparent pricing for these high-value, life-altering yet costly gene therapies.
February 29, 2024 – Bloomington, MN – Emerging Therapy Solutions® (ETS), an industry leader in providing cutting-edge services to help payers and other risk-bearing entities prepare for the accelerating growth in cell and gene therapies and other high-cost, complex treatments, today announced that it has recently contracted with the national Hemophilia Alliance Network Services (HANS) to provide network access at national negotiated rates to ETS payer clients for two hemophilia gene therapies at several of its participating hemophilia treatment centers (HTCs) across the country. This exceptional agreement will enable ETS to fulfill its mission to help payers and providers better manage the high costs associated with treatments for rare genetic diseases, so that more people can access these life-changing treatments.
To start, ETS has contracted rates with HANS which has a list of over 40 participating HTCs nationwide, with an expectation of adding other locations throughout the calendar year. HANS is currently working with its member list to determine gene therapy readiness and provide education on the agreement with ETS. Negotiated rates will help provide ETS clients with greater options for care, and with consistency and predictability for both biologic costs and contracted administration costs, ultimately saving money and changing lives.
According to Ashley Hume, ETS Chief Commercial Officer, “This opportunity to establish rates with the Hemophilia Alliance Network Services is an excellent way to continue serving our clients, and to lead in partnering with industry stakeholders to provide access to care at more predictable costs.”
Cell and gene therapies are some of the newest pharmaceutical innovations to treat and potentially cure disease, with 10-20 new cell and gene therapies estimated to be approved by the U.S. Food and Drug Administration (FDA) by 2025. The FDA has already approved two gene therapies for hemophilia. Hemgenix® (etranacogene dezaparvovec-drlc) from CLS Behring (CSL) was approved by the FDA in November 2022 for the treatment of adults with hemophilia B. Roctavian™ (valoctocogene roxaparvovec-rvox) from BioMarin Pharmaceutical Inc. was approved by the US Food and Drug Administration (FDA) in June 2023 for the treatment of adults with severe hemophilia A.
About Hemophilia
Hemophilia is an inherited (genetic) blood disorder in which the body’s normal clotting process is impaired, due to a gene mutation. The mutation causes a deficiency or abnormality in the development of coagulation factor, which is necessary for appropriate blood clotting. Severe hemophilia may cause prolonged bleeding from minor injuries or can occur spontaneously with bleeding into vital organs, joints and muscles. Hemophilia requires lifelong treatment, and due to the complexity, individuals are often referred to Hemophilia Treatment Centers (HTCs) for care.
About Hemophilia Alliance Network Services
As a recognized leader in the bleeding disorder community, the Hemophilia Alliance is a not-for-profit organization that comprises federally funded hemophilia treatment centers (HTCs) that either have, or are seeking to have, pharmacy programs under Section 340B of the Public Health Service Act. Through its Hemophilia Alliance Network Services entity, the Hemophilia Alliance supports HTCs by providing access to local, regional and national entities for dispensation of traditional bleeding disorders products and gene therapy products. The Hemophilia Alliance promotes the common interests of its member HTCs, providing support through advocacy, consultant expertise and organizational support in operations, regulatory, compliance, payer relations, legal updates affecting practices, and contract pharmacy.
About Emerging Therapy Solutions
Emerging Therapy Solutions (ETS) helps reinsurance and stop-loss payers, health plans and self-funded employers manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies. Learn more at emergingtherapies.com.
ETS Media Contact:
Sara Hakanson
SVP, Client Delivery Services
sara.hakanson@emergingtherapies.com
